DFS70 antibodies-biomarkers for the exclusion of ANA-associated autoimmune rheumatic diseases

LaboratoriumsMedizin

Volumn 38, Issue 6, 2015, Pages

  Conrad, Karsten ^a   Röber, Nadja ^a   Rudolph, Sebastian ^b   Mahler, Michael ^c  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b ADMEDIA MVZ GmbH   (Germany)

^c INOVA DIAGNOSTICS INC   (United States)

Author keywords

ANA associated autoimmune rheumatic diseases; Antinuclear antibodies (ANA); DFS70 antibodies

Indexed keywords

ANTIBODY; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; DFS70 ANTIBODY; DOUBLE STRANDED DNA ANTIBODY; LENS EPITHELIUM DERIVED GROWTH FACTOR ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY ISOLATION; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; HEP 2 CELL LINE; HUMAN; HUMAN CELL; LABORATORY DIAGNOSIS; RHEUMATIC DISEASE; SEROLOGY;

EID: 84989882861     PISSN: 03423026     EISSN: 14390477     Source Type: Journal    
DOI: 10.1515/labmed-2015-0040     Document Type: Article

References (42)

1. Mahler M, Meroni PL, Bossuyt X, Fritzler MJ. Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. J Immunol Res 2014;2014:315179.
2. Mahler M, Fritzler MJ. Epitope specificity and significance in systemic autoimmune diseases. Ann NY Acad Sci 2010;1183:267-87.
3. Tan EM, Zhang J. Autoantibodies to tumor-associated antigens: reporters from the immune system. Immunol Rev 2008;222:328-40.
4. Narciso-Schiavon JL, Freire FC, Suarez MM, Ferrari MV, Scanhola GQ, Schiavon LD, et al. Antinuclear antibody positivity in patients with chronic hepatitis C: clinically relevant or an epiphenomenon? Eur J Gastroenterol Hepatol 2009;21:440.6.
5. Tan EM, Feltkamp TE, Smolen JS, Butcher B, Dawkins R, Fritzler MJ, et al. Range of antinuclear antibodies in healthy individuals. Arthritis Rheum 1997;40:1601-11.
6. Conrad K, Schößler W, Hiepe F. Autoantikörper bei systemischen Autoimmunerkrankungen. Ein diagnostischer Leitfaden, 4. Auflage. Lengerich: Pabst Science Publishers, 2012.
7. Sack U, Conrad K, Csernok E, Frank I, Hiepe F, Krieger T, et al. Autoantikörpernachweis mittels indirekter Immunfluoreszenz an HEp-2-Zellen. J Lab Med 2012;36:135-41.
8. Wiik AS, Høier-Madsen M, Forslid J, Charles P, Meyrowitsch J. Antinuclear antibodies: a contemporary nomenclature using HEp-2 cells. J Autoimmun 2010;35:276-90.
9. Dellavance A, Viana VS, Leon EP, Bonfa ES, Andrade LE, Leser PG. The clinical spectrum of antinuclear antibodies associated with the nuclear dense fine speckled immunofluorescence pattern. J Rheumatol 2005;32:2144-9.
10. Mariz HA, Sato EI, Barbosa SH, Rodrigues SH, Dellavance A, Andrade LE. Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibodypositive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum 2011;63:191-200.
11. Ochs RL, Stein TW, Peebles CL, Gittes RF, Tan EM. Autoantibodies in interstitial cystitis. J Urol 1994;151:587-92.
12. Ochs RL, Muro Y, Si Y, Ge H, Chan EK, Tan EM. Autoantibodies to DFS 70 kd/transcription coactivator p75 in atopic dermatitis and other conditions. J Allergy Clin Immunol 2000;105:1211-20.
13. Ge H, Si Y, Roeder RG. Isolation of cDNAs encoding novel transcription coactivators p52 and p75 reveals an alternate regulatory mechanism of transcriptional activation. EMBO J 1998;17:6723-9.
14. Singh DP, Ohguro N, Kikuchi T, Sueno T, Reddy VN, Yuge K, et al. Lens epithelium-derived growth factor: effects on growth and survival of lens epithelial cells, keratinocytes, and fibroblasts. Biochem Biophys Res Commun 2000;267:373-81.
15. Shinohara T, Singh DP, Fatma N. LEDGF, a survival factor, activates stress-related genes. Prog Retin Eye Res 2002;21:341-58.
16. Kuwabara N, Itoh Y, Igarshi T, Fukunaga Y. Autoantibodies to lens epithelium-derived growth factor/transcription co-activator P75 (LEDGF/P75) in children with chronic nonspecific complaints and with positive antinuclear antibodies. Autoimmun 2009;42:492-6.
17. Yamada K, Senju S, Shinohara T, Nakatsura T, Murata Y, Ishihara M, et al. Humoral immune response directed against LEDGF in patients with VKH. Immunol Lett 2001;78:161-8.
18. Chin MS, Caruso RC, Detrick B, Hooks JJ. Autoantibodies to p75/LEDGF, a cell survival factor, found in patients with atypical retinal degeneration. J Autoimmun 2006;27:17-27.
19. Maertens G, Cherepanov P, Pluymers W, Busschots K, De Clercq E, Debyser Z, et al. LEDGF/p75 is essential for nuclear and chromosomal targeting of HIV-1 integrase in human cells. J Biol Chem 2003;278:33528-39.
20. Ogawa Y, Sugiura K, Watanabe A, Kunimatsu M, Mishima M, Tomita Y, et al. Autoantigenicity of DFS70 is restricted to the conformational epitope of C-terminal alpha-helical domain. J Autoimmun 2004;23:221-31.
21. Daniels T, Zhang J, Gutierrez I, Elliot ML, Yamada B, Heeb MJ, et al. Antinuclear autoantibodies in prostate cancer: immunity to LEDGF/p75, a survival protein highly expressed in prostate tumors and cleaved during apoptosis. Prostate 2005;62:14-26.
22. Okamoto M, Ogawa Y, Watanabe A, Sugiura K, Shimomura Y, Aoki N, et al. Autoantibodies to DFS70/LEDGF are increased in alopecia areata patients. J Autoimmun 2004;23:257-66.
23. Ayaki M, Ohoguro N, Azuma N, Majima Y, Yata K, Ibaraki N, et al. Detection of cytotoxic anti-LEDGF autoantibodies in atopic dermatitis. Autoimmun 2002;35:319-27.
24. Mahler M, Parker T, Peebles CL, Andrade LE, Swart A, Carbone Y, et al. Anti-DFS70/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases. J Rheumatol 2012;39:2104-10.
25. Watanabe A, Kodera M, Sugiura K, Usuda T, Tan EM, Takasaki Y, et al. Anti-DFS70 antibodies in 597 healthy hospital workers. Arthritis Rheum 2004;50:892-900.
26. Muro Y, Sugiura K, Morita Y, Tomita Y. High concomitance of disease marker autoantibodies in anti-DFS70/LEDGF autoantibodypositive patients with autoimmune rheumatic disease. Lupus 2008;17:171-6.
27. Muro Y, Sugiura K, Nakashima R, Mimori T, Akiyama M. Low prevalence of anti-DFS70/LEDGF antibodies in patients with dermatomyositis and other systemic autoimmune rheumatic diseases. J Rheumatol 2013;40:92-3.
28. Bizzaro N, Tonutti E, Visentini D, Alessio MG, Platzgummer S, Morozzi G, et al. Antibodies to the lens and cornea in anti-DFS70-positive subjects. Ann NY Acad Sci 2007;1107:174-83.
29. Pazini AM, Fleck J, dos Santos RS, Beck ST. Clinical relevance and frequency of cytoplasmic and nuclear dense fine speckled patterns observed in ANA-HEp-2. Bras J Rheumatol 2010;50:655-64.
30. Miyara M, Albesa R, Charuel JL, El Amri M, Fritzler MJ, Ghillani-Dalbin P, et al. Clinical phenotypes of patients with anti-DFS70/LEDGF antibodies in a routine ANA referral cohort. Clin Dev Immunol 2013;2013:703759.
31. Fitch-Rogalsky C, Steber W, Mahler M, Lupton T, Martin L, Barr SG, et al. Clinical and serological features of patients referred through a rheumatology triage system because of positive antinuclear antibodies. PLoS One 2014; e93812. DOI: 10.1371/journal.pone.0093812.
32. Mahler M, Miller FW, Fritzler MJ. Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. Autoimmun Rev 2014;13:367-71.
33. Petri M, Orbai AM, Alarcon GS, Gordon C, Merill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677-86.
34. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
35. Mahler M, Fritzler MJ. The clinical significance of the dense fine speckled immunofluorescence pattern on HEp-2 cells for the diagnosis of systemic autoimmune diseases. Clin Dev Immunol 2012;494356. DOI: 10.1155/2012/494356.
36. Mahler M, Hanly JG, Fritzler MJ. Importance of the dense fine speckled pattern on HEp-2 cells and anti-DFS70 antibodies for the diagnosis of systemic autoimmune diseases. Autoimmun Rev 2012;11:642-45.
37. Mahler M, Raijmakers R, Fritzler MJ. Challenges and controversies in autoantibodies associated with systemic rheumatic diseases. Curr Rheumatol Rev 2007;3:67-78.
38. Xie C, Kim HJ, Haw JG, Kalbasi A, Gardner BK, Li G, et al. A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from non-malignant cases. J Translat Med 2011, 9:43. Available at: http://www.translational-medicine.com/content/9/1/43.
39. Bizzaro N, Tonutti E, Villalta D. Recognizing the dense fine speckled/lens epithelium-derived growth factor/p75 pattern on HEp-2 cells: not an easy task! Comment on the article by Mariz et al. Arthritis Rheum 2011;63:4036-7.
40. Goto N, Sugiura K, Ogawa Y, Watanabe A, Onouchi H, Tomita Y, et al. Anti-p80 coilin autoantibodies react with a conserved epitope and are associated with anti-DFS70/LEDGF autoantibodies. J Autoimmun 2006;26:42-51.
41. Agmon-Levin N, Damoiseaux J, Kallenberg C, Sack U, Witte T, Herold M, et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as antinuclear antibodies. Ann Rheum Dis 2014;73:17-23.
42. Meroni PL, Schur PH. ANA screening: an old test with new recommendations. Ann Rheum Dis 2010;69:1420-2.